Last reviewed · How we verify
Pentacel®: DTaP-IPV/Hib combined — Competitive Intelligence Brief
phase 3
vaccine
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Pentacel®: DTaP-IPV/Hib combined (Pentacel®: DTaP-IPV/Hib combined) — Sanofi Pasteur, a Sanofi Company. Pentacel stimulates the body's immune response to produce antibodies against diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pentacel®: DTaP-IPV/Hib combined TARGET | Pentacel®: DTaP-IPV/Hib combined | Sanofi Pasteur, a Sanofi Company | phase 3 | vaccine | ||
| Comirnaty | BNT162b2 (tozinameran) | Pfizer Inc. | marketed | vaccine | SARS-CoV-2 virus | 2021-08-23 |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| Pneumococcal polysaccharide vaccine | Pneumococcal polysaccharide vaccine | Celgene | marketed | Polysaccharide vaccine | Streptococcus pneumoniae capsular polysaccharides (23 serotypes) | |
| PPV Vaccine | PPV Vaccine | Fakultas Kedokteran Universitas Indonesia | marketed | Polysaccharide vaccine | Streptococcus pneumoniae capsular polysaccharides | |
| Tdap Vaccine Administration | Tdap Vaccine Administration | Institute of Arthritis Research | marketed | vaccine | ||
| PCV13 alone | PCV13 alone | Korea University Guro Hospital | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae polysaccharide capsule (13 serotypes) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (vaccine class)
- Pfizer · 20 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
- GlaxoSmithKline · 12 drugs in this class
- Merck Sharp & Dohme LLC · 12 drugs in this class
- Centers for Disease Control and Prevention · 9 drugs in this class
- Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
- Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
- Beijing Center for Disease Control and Prevention · 6 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
- Sinovac Biotech Co., Ltd · 4 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pentacel®: DTaP-IPV/Hib combined CI watch — RSS
- Pentacel®: DTaP-IPV/Hib combined CI watch — Atom
- Pentacel®: DTaP-IPV/Hib combined CI watch — JSON
- Pentacel®: DTaP-IPV/Hib combined alone — RSS
- Whole vaccine class — RSS
Cite this brief
Drug Landscape (2026). Pentacel®: DTaP-IPV/Hib combined — Competitive Intelligence Brief. https://druglandscape.com/ci/pentacel-dtap-ipv-hib-combined. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab